COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY

Ji Hwan Lee, Sung Chul Lee, Hyesun Kim, Christopher Seungkyu Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

PURPOSE: To compare the short-term therapeutic efficacy of oral spironolactone treatment with that of half-dose photodynamic therapy (PDT) in patients with nonresolving central serous chorioretinopathy. METHODS: This retrospective, interventional, comparative study included 41 patients with nonresolving central serous chorioretinopathy who exhibited subretinal fluid accumulation for more than 3 months. Of the 41 patients, 18 (18 eyes) received oral spironolactone treatment and 23 (23 eyes) received half-dose PDT. Treatment outcomes, including the central macular thickness, subretinal fluid height, subfoveal choroidal thickness, and best-corrected visual acuity, were measured at baseline and 1 and 3 months after treatment. RESULTS: There were no differences in baseline characteristics between the two groups. The central macular thickness and the subretinal fluid height significantly decreased at 1 and 3 months after treatment. The central macular thickness at 1 month was lesser in the PDT group than in the spironolactone group. The subfoveal choroidal thickness decreased at 1 and 3 months only in the PDT group, whereas best-corrected visual acuity showed a significant improvement at 3 months in both groups. CONCLUSION: Our results suggest that the short-term efficacy of oral spironolactone treatment for the management of nonresolving central serous chorioretinopathy is comparable with that of half-dose PDT, with an excellent safety profile.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalRetina (Philadelphia, Pa.)
Volume39
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Central Serous Chorioretinopathy
Spironolactone
Photochemotherapy
Subretinal Fluid
Visual Acuity
Therapeutics
Safety

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{90315cf98e2c4538bbc5178056e50a40,
title = "COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY",
abstract = "PURPOSE: To compare the short-term therapeutic efficacy of oral spironolactone treatment with that of half-dose photodynamic therapy (PDT) in patients with nonresolving central serous chorioretinopathy. METHODS: This retrospective, interventional, comparative study included 41 patients with nonresolving central serous chorioretinopathy who exhibited subretinal fluid accumulation for more than 3 months. Of the 41 patients, 18 (18 eyes) received oral spironolactone treatment and 23 (23 eyes) received half-dose PDT. Treatment outcomes, including the central macular thickness, subretinal fluid height, subfoveal choroidal thickness, and best-corrected visual acuity, were measured at baseline and 1 and 3 months after treatment. RESULTS: There were no differences in baseline characteristics between the two groups. The central macular thickness and the subretinal fluid height significantly decreased at 1 and 3 months after treatment. The central macular thickness at 1 month was lesser in the PDT group than in the spironolactone group. The subfoveal choroidal thickness decreased at 1 and 3 months only in the PDT group, whereas best-corrected visual acuity showed a significant improvement at 3 months in both groups. CONCLUSION: Our results suggest that the short-term efficacy of oral spironolactone treatment for the management of nonresolving central serous chorioretinopathy is comparable with that of half-dose PDT, with an excellent safety profile.",
author = "Lee, {Ji Hwan} and Lee, {Sung Chul} and Hyesun Kim and Lee, {Christopher Seungkyu}",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/IAE.0000000000001913",
language = "English",
volume = "39",
pages = "127--133",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. / Lee, Ji Hwan; Lee, Sung Chul; Kim, Hyesun; Lee, Christopher Seungkyu.

In: Retina (Philadelphia, Pa.), Vol. 39, No. 1, 01.01.2019, p. 127-133.

Research output: Contribution to journalArticle

TY - JOUR

T1 - COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY

AU - Lee, Ji Hwan

AU - Lee, Sung Chul

AU - Kim, Hyesun

AU - Lee, Christopher Seungkyu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - PURPOSE: To compare the short-term therapeutic efficacy of oral spironolactone treatment with that of half-dose photodynamic therapy (PDT) in patients with nonresolving central serous chorioretinopathy. METHODS: This retrospective, interventional, comparative study included 41 patients with nonresolving central serous chorioretinopathy who exhibited subretinal fluid accumulation for more than 3 months. Of the 41 patients, 18 (18 eyes) received oral spironolactone treatment and 23 (23 eyes) received half-dose PDT. Treatment outcomes, including the central macular thickness, subretinal fluid height, subfoveal choroidal thickness, and best-corrected visual acuity, were measured at baseline and 1 and 3 months after treatment. RESULTS: There were no differences in baseline characteristics between the two groups. The central macular thickness and the subretinal fluid height significantly decreased at 1 and 3 months after treatment. The central macular thickness at 1 month was lesser in the PDT group than in the spironolactone group. The subfoveal choroidal thickness decreased at 1 and 3 months only in the PDT group, whereas best-corrected visual acuity showed a significant improvement at 3 months in both groups. CONCLUSION: Our results suggest that the short-term efficacy of oral spironolactone treatment for the management of nonresolving central serous chorioretinopathy is comparable with that of half-dose PDT, with an excellent safety profile.

AB - PURPOSE: To compare the short-term therapeutic efficacy of oral spironolactone treatment with that of half-dose photodynamic therapy (PDT) in patients with nonresolving central serous chorioretinopathy. METHODS: This retrospective, interventional, comparative study included 41 patients with nonresolving central serous chorioretinopathy who exhibited subretinal fluid accumulation for more than 3 months. Of the 41 patients, 18 (18 eyes) received oral spironolactone treatment and 23 (23 eyes) received half-dose PDT. Treatment outcomes, including the central macular thickness, subretinal fluid height, subfoveal choroidal thickness, and best-corrected visual acuity, were measured at baseline and 1 and 3 months after treatment. RESULTS: There were no differences in baseline characteristics between the two groups. The central macular thickness and the subretinal fluid height significantly decreased at 1 and 3 months after treatment. The central macular thickness at 1 month was lesser in the PDT group than in the spironolactone group. The subfoveal choroidal thickness decreased at 1 and 3 months only in the PDT group, whereas best-corrected visual acuity showed a significant improvement at 3 months in both groups. CONCLUSION: Our results suggest that the short-term efficacy of oral spironolactone treatment for the management of nonresolving central serous chorioretinopathy is comparable with that of half-dose PDT, with an excellent safety profile.

UR - http://www.scopus.com/inward/record.url?scp=85050357301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050357301&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000001913

DO - 10.1097/IAE.0000000000001913

M3 - Article

C2 - 29095358

AN - SCOPUS:85050357301

VL - 39

SP - 127

EP - 133

JO - Retina

JF - Retina

SN - 0275-004X

IS - 1

ER -